Activities of LY333328 and Vancomycin Administered Alone or in Combination with Gentamicin against Three Strains of Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model

Staphylococcus aureus with intermediate glycopeptide susceptibility (glycopeptide-intermediate S. aureus [GISA]) has been isolated from patients with apparent therapy failures. We studied the killing activity of vancomycin over a range of simulated conventional doses (1 to 1.5 g every 12 h) against...

詳細記述

書誌詳細

出版年:	Antimicrob Agents Chemother
主要な著者:	Aeschlimann, Jeffrey R., Allen, George P., Hershberger, Ellie, Rybak, Michael J.
フォーマット:	Artigo
言語:	Inglês
出版事項:	American Society for Microbiology (ASM) 2000
主題:	Experimental Therapeutics
オンライン･アクセス:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101591/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11036011/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.11.2991-2998.2000
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!